CN-122012339-A - Gluconobacter nicotianae, uric acid reducing microbial inoculum and application thereof

Abstract

The invention belongs to the technical field of uric acid reduction by microorganisms, and particularly relates to a bacillus nicotianae, a uric acid reducing microbial agent and application thereof. The glutamic acid bacillus (Glutamicibacter nicotianae) is FL1-1 strain, the preservation number is CGMCC No.37236, and the preservation date is 2025, 12 and 29. The FL1-1 strain can grow in a bile salt environment with a pH of 3.0 or more and a bile salt concentration of 0.3% or less. The uric acid of FL1-1 reaches 95.96% in 72h, and the uric acid degradation capability can be improved by adding a proper amount of Fe 2+ into a culture medium. FL1-1 has good gastrointestinal tract environmental tolerance, remarkable uric acid reducing capability, antibacterial activity and antibiotic resistance spectrum.

Inventors

• LIAO FEI
• HE JIE

Assignees

• 贵州农业职业学院

Dates

Publication Date

20260512

Application Date

20260318

Claims (8)

1. 1. The bacillus glutamicum (Glutamicibacter nicotianae) is characterized in that the bacillus glutamicum is a FL1-1 strain, the preservation number is CGMCC No. 37236, the preservation date is 2025, 12 and 29 days, and the FL1-1 strain can grow in a bile salt environment with the pH value of more than or equal to 3.0 and the bile salt concentration of less than or equal to 0.3%.
2. 2. The uric acid reducing microbial inoculum based on the bacillus nicotianae as claimed in claim 1 is characterized by comprising a bacillus nicotianae microbial inoculum and auxiliary materials, wherein the bacillus nicotianae microbial inoculum is a bacterial liquid of the bacillus nicotianae or freeze-dried bacterial powder of the bacillus nicotianae, and the auxiliary materials are salts containing Fe 2+ or a solution thereof.
3. 3. The uric acid reducing microbial agent based on the bacillus nicotianae as defined in claim 2, wherein the viable count of the microbial liquid of the bacillus nicotianae is greater than or equal to 10 8 CFU/mL.
4. 4. The uric acid reducing microbial agent based on the bacillus nicotianae as defined in claim 3, wherein the viable count of the bacillus nicotianae bacterial liquid is 10 8 CFU/mL~10 9 CFU/mL.
5. 5. The uric acid reducing microbial agent based on the glutamic acid bacillus of the tobacco according to claim 2, wherein the ratio of the number of viable bacteria in the uric acid reducing microbial agent to Fe 2+ in auxiliary materials is 5 multiplied by 10 8 CFU~5×10 9 CFU, and the ratio is 3.66 mg-10.96 mg.
6. 6. The uric acid-reducing microbial agent based on Gluconobacter nicotianae as defined in claim 5, wherein the ratio of the number of viable bacteria in the uric acid-reducing microbial agent to Fe 2+ in the adjuvant is 5X 10 9 CFU to 5.48mg.
7. 7. The uric acid lowering preparation based on Gluconobacter nicotianae of claim 2, wherein the Fe 2+ -containing salt is ferrous sulfate.
8. 8. The application of a uric acid reducing bacterial agent based on Gluconobacter nicotianae in preparing uric acid reducing medicines according to claim 2.

Description

Gluconobacter nicotianae, uric acid reducing microbial inoculum and application thereof Technical Field The invention belongs to the technical field of uric acid reduction by microorganisms, and particularly relates to a bacillus nicotianae, a uric acid reducing microbial agent and application thereof. Background Hyperuricemia in poultry is a common metabolic disease caused by purine metabolic disturbance and is mainly characterized by abnormal elevation of uric acid concentration in blood. Under the intensive culture mode, the disease is particularly prominent, and visceral gout or joint gout is often caused, so that slow growth of poultry, reduced feed conversion rate, organ injury and even death are caused, and obvious economic loss is caused for the breeding industry. Because poultry lacks endogenous urate oxidase physiologically, uric acid cannot be effectively decomposed into water-soluble allantoin, and thus purine metabolic end products of the poultry accumulate in the form of uric acid, which is the root cause of the susceptibility of the poultry to hyperuricemia. At present, chemical medicines such as low-protein ration and allopurinol are mainly adjusted in production, but the chemical medicines possibly affect production performance, and the chemical medicines have the risks of medicine residues, potential toxic and side effects and bacterial drug resistance. Compared with the direct addition of an enzyme preparation, probiotics can directly reach the intestinal tract through oral administration, continuously generate enzyme activity in local parts, and simultaneously have multiple probiotic functions of regulating intestinal flora, inhibiting pathogenic bacteria, enhancing immunity and the like, so that the effect of one bacterium is realized. However, the existing uric acid-reducing microorganisms are difficult to survive in the environment of pH value and choline concentration in which gastric acid and bile salts exist, and some microorganisms have pathogenicity and hemolysis and cannot be used as additives of feed. Disclosure of Invention In order to solve the technical problems, the invention provides a bacillus nicotianae, uric acid reducing bacterial agent and application thereof. In order to facilitate an understanding of the present invention, materials used in the present invention and shorthand for them are now listed below: Gentamicin, abbreviated GEN. Ceftriaxone, abbreviated as CTR. Ciprofloxacin, abbreviated CIP. Clindamycin, abbreviated CC. Chloramphenicol, abbreviated as C. Cefalexin, abbreviated CN. Minocycline, abbreviated MI. Levofloxacin, abbreviated LVX. Erythromycin, abbreviated as E. Vancomycin, abbreviated VAN. Piperacillin, abbreviated PIP. Amikacin is abbreviated as AMK. Oxacillin, abbreviated OX. Tetracyclines, abbreviated TET. Imipenem, abbreviated IPM. The compound is Xinnoming, abbreviated as SXT. The first object of the present invention is to provide a glutamic acid bacterium (Glutamicibacter nicotianae) of the type FL1-1 strain, having a preservation number of CGMCC No. 37236 and a preservation date of 2025, 12 months and 29 days, wherein the FL1-1 strain can grow in a bile salt environment having a pH of 3.0 or more and a bile salt concentration of 0.3% or less. The invention provides a uric acid reducing microbial inoculum based on the bacillus nicotianae, which consists of the bacillus nicotianae microbial inoculum and auxiliary materials. The bacillus cereus bacterial agent is bacterial liquid of bacillus cereus or freeze-dried bacterial powder of bacillus cereus, and the auxiliary material is a salt or solution containing Fe 2+. Preferably, the viable count of the bacterial liquid of the glutamic acid bacillus of the tobacco is more than or equal to 10 8 CFU/mL. Preferably, the viable count of the bacillus subtilis liquid is 10 8CFU/mL~109 CFU/mL. Preferably, the ratio of the viable count in the uric acid reducing microbial inoculum to Fe 2+ in the auxiliary material is 5 multiplied by 10 8CFU~5×109 CFU, 3.66 mg-10.96 mg. Preferably, the ratio of the viable count in the uric acid reducing microbial inoculum to Fe 2+ in the auxiliary material is 5X 10 9 CFU to 5.48mg. Preferably, the Fe 2+ -containing salt is ferrous sulfate. Preferably, the concentration of the ferrous sulfate is 0.010 g/L-0.03 g/L. Preferably, the concentration of the ferrous sulfate is 0.015g/L. The third object of the invention is to provide an application of a uric acid reducing bacterial agent based on Gluconobacter nicotianae in uric acid reduction. Biological information preservation description The strain related to the invention is as follows: The strain of the glutamic acid bacillus of tobacco is FL1-1 and is preserved in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) on the 12 th month 29 of 2025, the proposed classification is named Glutamicibacter nicotianae, the preservation number is CGMCC No. 37236, and the